However, treatment of Nrf1-expressing cells with 12-O-tetradecanoylphorbol-13- acetate (TPA, a tumor promotor to induce AP-1 that comprises c-Jun and c-Fos) resulted in a significant decrease in the ARE-driven reporter activity (Figure 7D). Here, NRF1 is linked to neoplasm.